Pascal Deschatelets - Apr 21, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol
APLS
Transactions as of
Apr 21, 2022
Transactions value $
-$167,040
Form type
4
Date filed
5/2/2022, 08:05 PM
Previous filing
Feb 14, 2022
Next filing
Jun 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Other $0 -1.88K -0.21% $0.00 892K Apr 21, 2022 Direct F1
transaction APLS Common Stock Options Exercise $10.7K +4K +0.45% $2.67* 896K Apr 29, 2022 Direct F2
transaction APLS Common Stock Sale -$178K -4K -0.45% $44.43 892K Apr 29, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Other $0 -11.3K -100% $0.00* 0 Apr 21, 2022 Common Stock 11.3K $44.90 Direct F3, F4
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -4K -1.08% $0.00 365K Apr 29, 2022 Common Stock 4K $2.67 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2 This is a scheduled exercise and sale from a 10B5-1 trading plan.
F3 This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
F4 This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.
F5 This stock option was granted on 12/5/2013 and is fully vested.